Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Conclusions:
Our results show that outcomes in HER2+ patients with early BC not receiving anti-HER2 therapy strongly depend on HR expression. The very high early risk of relapse seen in HER2 + HR- patients is particularly relevant in health care settings with limited access to adjuvant anti-HER2 treatment. The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2 + HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy.

Source: Breast Cancer Research - April 16, 2015 Category: Cancer & Oncology Authors: Kathrin Strasser-WeipplNora HorickIan SmithJoyce O¿ShaughnessyBent EjlertsenFrances BoyleAman BuzdarPierre FumoleauWilliam GradisharMiguel MartinBeverly MoyMartine Piccart-GebhartKathleen PritchardDeborah LindquistErica RappoldDianne FinkelsteinPaul Goss Source Type: research